ICML 2023 | Long-term safety analysis of pirtobrutinib in R/R B-cell malignancies

Pirtobrutinib is a non-covalent reversible BTK inhibitor in development in relapsed/refractory B-cell malignancies. And the BRUIN clinical trial has enrolled nearly 800 patients over the last few years. And the median follow-up across the studies is generally relatively short, and so the purpose of this abstract really is to look at longer term toxicity. We know that BTK inhibitors in general tend to accumulate toxicity as time goes by. And one of the really important things with this agent, certainly early on, is the toxicity profile looks very favorable, very minimal grade three and above toxicities and low discontinuation rates. And so the purpose here is to look at a cohort within the trial that have been on drug for more than or equivalent to a year. And essentially this is over 300 patients in this cohort. And it shows reassuringly that those patients who’ve been on the drug for that period of time actually don’t seem to be developing new or concerning toxicity, so really demonstrating that pirtobrutinib is a very well tolerated non-covalent BTK inhibitor.